2. DRUG AND EXCIPIENT PROFILES AND METHODS USED...
Transcript of 2. DRUG AND EXCIPIENT PROFILES AND METHODS USED...
65
2. DRUG AND EXCIPIENT PROFILES AND METHODS USED FOR THE ANALYSIS OF FAMOTIDINE
2.1. Famotidine:
Famotidine is histamine H2 -receptor antagonist.
2.1.1. Synonym: Famotidinum.
2.1.2. Proprietary names1:
Amfamox; Brolin; Dispromil; Famodil; Famodine; Famosan;
Famoxal; Ganor; Gastor; Gastropen; Ifada; Lecedil; Motiax; Pepcid;
Pepcidac; Pepcidin; Pepcidine; Pepdine; Pepdul; Ulcusan; Ulfinol.
2.1.3. Structure of famotidine:
Famotidine is chemically 3-[[[2-[(Aminoiminomethyl) amino]-
4thiazolyl] methyl] thio]-N-(aminosulfonyl) propanimidamide.
2.1.4. Molecular formula: C8H15N7O2S3
2.1.5. Molecular weight: 337.5
2.1.6. Physico-chemical properties:
2.1.6.1. Description:
A white to pale yellowish white crystalline powder with melting
point in the range of 163° C to 164° C.
66
2.1.6.2. Solubility:
It is very slightly soluble in water and dehydrated alcohol;
practically insoluble in acetone, alcohol, chloroform, ether and ethyl
acetate; slightly soluble in methyl alcohol; freely soluble in dimethyl
formamide and glacial acetic acid. It dissolves in dilute mineral acids.
2.1.6.3. Storage:
It should be stored in well closed, light resistant container.
2.1.6.4. Dissociation constant:
pKa = 7.06
2.1.6.5. Partition coefficient :
Log P (octanol/water) = −0.64
2.1.7. Pharmacokinetics:
2.1.7.1. Absorption:
Famotidine is readily but incompletely absorbed after oral
administration. Oral bioavailability of famotidine is about 40–50%2,3.
Peak plasma concentration of famotidine in humans is
70.41±30.39 ng/mL4. Peak plasma levels occur in 1-3 hrs following
intravenous3,5,6 and 1-4 hrs following oral administration3,6,7. The
serum therapeutic concentration of famotidine is 20 - 60 ng/mL1,8.
2.1.7.2. Distribution:
The drug is widely distributed in body tissues like kidney, liver,
pancreas and submandibular gland2 and can be detected in breast
67
milk. Plasma protein binding of famotidine is 15–20%2,5 and the volume
of distribution of the drug at steady state ranges from 1.0 to 1.3 L/Kg9.
2.1.7.3. Metabolism:
It is metabolized in the liver to form inactive famotidine S-oxide
(S-famotidine). It undergoes minimal first-pass metabolism5.
2.1.7.4. Excretion:
Principally it is excreted in urine2,5,10. 25–30% of famotidine is
excreted as unchanged after oral administration and 65–80% after
intravenous administration2,10. Famotidine has an elimination half life
of 2.5-3.5 hrs2,5,10. A prolongation of elimination half life and a decrease
in total body clearance and renal clearance are observed in patients
with renal failure indicating that dosage adjustment may be necessary
in patients who have renal insufficiency.
2.1.8. Mechanism of action:
H2-receptor antagonists inhibit acid production by reversibly
competing with histamine for binding to H2-receptors on the basolateral
membrane of parietal cells11. Famotidine competitively inhibits
histamine actions at all H2-receptors but its main clinical use is
inhibition of gastric acid secretion. It inhibits histamine stimulated and
gastrin stimulated acid secretion. It decreases both basal and food
stimulated acid secretion by 90% or more, but promotes healing of
duodenal ulcers as shown by numerous clinical trials12.
68
2.1.9. Indications and usage:
Famotidine is indicated13 in the following conditions like,
� Short term treatment of active duodenal ulcer.
� Maintenance therapy for duodenal ulcer patients at reduced
dosage after healing of an active ulcer.
� Short term treatment of active benign gastric ulcer.
� Short term treatment of gastro oesophageal reflux disease
(GERD).
� Treatment of pathological hypersecretory conditions
(e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas).
2.1.10. Contraindications:
Famotidine should not be administered to patients with a history
of hypersensitivity to other H2-receptor antagonists.
2.1.11. Drug interactions:
No drug interactions have been identified. Studies with
famotidine in man, in animal models and in vitro have shown no
significant interference with the disposition of drug.
2.1.12. Adverse reactions11:
The overall incidence of adverse effects is low (<3%) and well
tolerated. The most frequent adverse effects include diarrhoea,
dizziness, fatigue, muscle pain, transient rashes, hypergastrinemia.
Less common adverse effects include those affecting the CNS
(confusion, delirium, hallucinations, slurred speech and headache)
69
which occur primarily with intravenous administration of the drug. No
major teratogenic risk has been associated with famotidine; caution is
nevertheless warranted when they are used in pregnancy.
2.1.13. Over dosage:
Oral doses of up to 640 mg/day have been given to adult patients
with pathological hyper secretory conditions with no serious adverse
effects.
2.1.14. Dosage and administration:
2.1.14.1. Duodenal ulcer:
In acute therapy, the recommended adult oral dose for active
duodenal ulcer is 40 mg once a day at bedtime. A regimen of 20 mg
twice daily is also effective. For the maintenance therapy an adult dose
of 20 mg once a day at bedtime is recommended.
2.1.14.2. Benign gastric ulcer:
The recommended adult oral dosage for active benign gastric
ulcer is 40 mg once a day at bedtime.
2.1.14.3. Gastro oesophageal reflux disease (GERD):
The recommended oral dosage for adult patients with GERD
symptoms is 20 mg twice daily for up to 6 weeks. The recommended
oral dosage for adult patients with oesophagitis including erosions,
ulcerations and accompanying symptoms due to GERD is
20 or 40 mg twice daily for up to 12 weeks.
70
Oral suspension of 0.5 mg/kg up to 8 weeks once daily for
patients less than 3 months of age and twice daily for patients of age
above 3 months up to 1 year.
2.2. Excipients used in the present study:
2.2.1. Polyethylene oxide (PEO)14:
In recent years polyethylene oxide (PEO) has attracted much
attention as a polymeric excipient that can be used in formulations for
different purposes. Formulations with PEO have been extruded to make
different products such as swellable and erodible implants15, scaffolds
for tissue engineering16 or in the production of micelles with
amphiphilic drugs17.
However, PEOs are mostly used to produce
controlled release solid dosage forms such as matrices, reservoirs or
coated cores18-20. PEOs control the release of the active moiety either by
swelling (large molecular weight, >2 MDa) or by eroding and swelling
(small molecular weight, <0.9 MDa), forming a hydrogel in the water. In
both cases, water triggers the process of erosion and/or swelling.
Due to physical and chemical stability, compressibility, high
swelling ability and good solubility in water, PEOs have been proposed
as alternatives to cellulose or other ethylene glycol derivatives in the
production of tablets or granules.
Recently, PEOs have been used in mixtures processed by hot
melt extrusion for the preparation of sustained release mucoadhesive
matrix films21,22. PEO was selected for the development of floating
tablets in combination with sodium bicarbonate due to its high swelling
71
ability which facilitate the release of drug through diffusion in a
controlled manner. In the present study, for the first time PEO is being
evaluated as controlled release hydrophilic polymer for the development
of effervescent gastric floating matrix tablets of famotidine.
2.2.1.1. Non proprietary names23:
Polyethylene oxide (USP)
2.2.1.2. Synonyms:
Polyox, Polyoxirane, Polyoxyethylene
2.2.1.3. Description:
It is a white to off-white, free flowing powder with slight
ammonical odor.
2.2.1.4. Formula: C2nH4n+2On+1
PEO is a nonionic homopolymer of ethylene oxide, where ‘n’
represents the average number of oxyethylene groups (about 2000 to
over 100000). It may contain up to 3% of silicon dioxide.
2.2.1.5. Typical properties:
Angle of repose : 34°
Density(true) : 1.3 gm/cc
Melting point : 65-70° C
Moisture content : <1%
72
2.2.1.6. Solubility:
It is soluble in water and in a number of common organic
solvents such as acetonitrile, chloroform and methylene chloride and
insoluble in aliphatic hydrocarbons, ethylene glycol and most alcohols.
2.2.1.7. Pharmaceutical applications:
� Used as a tablet binder at a concentration range of 5- 85%
� The higher molecular weight grades provide delayed drug
release via the hydrophilic matrix approach.
� As an excellent mucoadhesive polymer.
� Low levels of PEO are effective thickeners.
� PEO films demonstrate good lubricity when wet. This property
has been utilized in the development of coatings for medical
devices.
� PEO can be radiation cross linked in solution to produce a
hydrogel. The hydrogels so produced have been used in
wound-care applications.
2.2.1.8. Storage conditions:
It should be stored in tightly sealed container in a cool and dry
place.
73
In the present study, effervescent gastric floating matrix tablets
were prepared using two viscosity grades of PEO as matrix forming
polymer for controlled release of famotidine. The grades of polyethylene
oxides used in the present study and their viscosities24 are:
PEO grade Mol. Wt. Viscosity (cps)
WSR 303 7,000,000 7,500 – 10,000 (1% solution)
WSR N-12K 1,000,000 400-800 (2% solution)
2.2.2. Glyceryl behenate25:
Glyceryl behenate is a hydrophobic, non swelling, wax material
commonly used as a lubricant. It consists of a mixture of mono-,
di- and tribehenate of glycerol (18%, 52% and 28% in weight,
respectively). Over the past decade, glyceryl behenate has been used for
controlled release applications by direct compression and more recently
by hot melt coating26-28, melt granulation or pelletization29,30 or the
formation of solid–lipid nanoparticles31. Due to its low density
(0.942 g/cm3) and controlled release nature, it is used for development
of gastric floating matrix tablets of famotidine without the use of
effervescent.
GRAS committee accepted it for use as a food additive in Europe.
Glyceryl behenate was included in the FDA’s inactive ingredients guide
(capsules and tablets) and in the Canadian list of acceptable non-
medicinal ingredients.
74
2.2.2.1. Nonproprietary names32:
Glyceryl behenate (USP-NF)
2.2.2.2. Synonyms:
Compritol 888 ATO; 2,3-dihydroxypropyl docosanoate;
docosanoic acid, 2,3-dihydroxypropyl ester; glyceryl monobehenate.
2.2.2.3. Description:
Glyceryl behenate occurs as a fine white to off-white free flowing
powder or hard waxy mass with a faint odor, tasteless, non-reactive
with other formulation ingredients.
2.2.2.4. Formula: C69H134O6
The USP NF 23 describes glyceryl behenate as a mixture of
glycerides of fatty acids, mainly behenic acid. It specifies that the
content of 1-monoglycerides should be 12.0–18.0%.
2.2.2.5. Typical properties:
Molecular weight : 1059.8 gm/mole
Melting point : 65–77° C
Water content (%) : Not more than 0.5%
Acid value : ≤4
Iodine value : ≤3
Saponification value : 145–165
Residue on ignition : ≤0.1%
Heavy metals : ≤0.001%
Content of 1-monoglycerides : 12.0–18.0%
Free glycerin : ≤1.0%
75
2.2.2.6. Solubility:
Glyceryl behenate is soluble, when heated, in chloroform and
dichloromethane. It is practically insoluble in ethanol (95%), hexane,
mineral oil and water.
2.2.2.7. Pharmaceutical applications:
Glyceryl behenate is used in cosmetics, foods and oral
pharmaceutical formulations. In cosmetics, it is mainly used as a
viscosity-increasing agent.
Table 2.1: Uses of glyceryl behenate
Use Concentration (%)
Lipophilic matrix or coating for sustained released tablets and capsules
>10.0
Tablet and capsule lubricant 1.0–3.0
Viscosity-increasing agent in silicon gels (cosmetics)
1.0–15.0
Viscosity-increasing agent in w/o or o/w emulsions (cosmetics)
1.0–5.0
In pharmaceutical formulations, glyceryl behenate is mainly used
as a tablet and capsule lubricant33 and as a lipidic coating excipient. It
has been investigated for the encapsulation of various drugs such as
retinoids34. It has also been investigated for use in the preparation of
sustained release tablets35-38, as a matrix-forming agent for the
controlled release of water-soluble drugs38 and as a lubricant in oral
solid dosage formulations and it can also be used as a hot-melt coating
agent sprayed onto a powder39.
76
2.2.2.8. Storage conditions:
Glyceryl behenate should be stored in a tightly sealed container
below 35° C temperature.
2.3. Estimation of famotidine:
Analytical methods for the estimation of famotidine that are
available for the estimation in pharmaceutical formulations and
biological fluids include high performance liquid chromatography
(HPLC)40-46, thin layer chromatography47-49, mass spectrometry50-52,
UV-Visible Spectrophotometric method53,54.
2.3.1. Method used for estimation of famotidine in the present study:
UV spectrophotometric method based on the measurement of
absorbance at 265 nm was selected for the in vitro analysis of
famotidine in the present work55. The calibration curve was constructed
in 0.1 N HCl.
2.3.1.1. Stock solution:
50 mg of famotidine was dissolved in sufficient amount of 0.1N
HCl in a 50 mL volumetric flask and the solution was made up to the
mark with 0.1N HCl.
2.3.1.2. Standard solution:
The stock solution was diluted subsequently with 0.1N HCl to get
a series of dilutions containing 2, 4, 6, 8 and 10 µg/mL. The
absorbance of these solutions was measured at 265 nm against blank.
77
All the estimations were done in triplicate and average values are
reported.
2.3.1.3. Results and discussion:
Famotidine is freely soluble in 0.1 N HCl. The concentrations of
famotidine and the corresponding absorbance values are given in
Table 2.2. The standard curve for famotidine was plotted against
concentration and the calibration curve is shown in Fig. 2.1.
Table 2.2: Concentration versus absorbance values for the estimation of famotidine
Concentration (µg/mL)
UV Absorbance (mean ± s.d.)
2 0.090 ± 0.02
4 0.170 ± 0.03
6 0.233 ± 0.12
8 0.314 ± 0.21
10 0.386 ± 0.18
y = 0.0283x + 0.0077r = 0.9989
0.00
0.10
0.20
0.30
0.40
0 2 4 6 8 10
Absorbance
Concentration (µg/mL)
Fig. 2.1: Calibration curve for the estimation of famotidine
The present analytical method obeyed Beer’s law in the
concentration range 2-10 µg/mL and is suitable for the estimation of
78
famotidine. The correlation coefficient (r) was found to be 0.9989,
indicating positive correlation between the concentration of famotidine
and the corresponding absorbance values.
2.3.2. HPLC method for the estimation of famotidine in human plasma samples:
Few HPLC methods have been reported for the estimation of
famotidine in human plasma samples40-46. Most of them are
complicated due to the extraction and evaporation processes.
The HPLC method of Zarghi et al.43, was modified and used for
the estimation of famotidine in human plasma samples obtained in the
in vivo study. In the present study, plasma samples were processed by
protein precipitation method instead of extraction method in order to
avoid the use of organic solvents and protein free plasma samples were
directly injected into the HPLC column.
2.3.2.1. Instrument details:
A gradient HPLC (Shimadzu, Class VP series) with two
LC-10AT VP pumps, variable wavelength programmable Photo Diode
Array (PDA) detector, SPD-M10A VP was used. The HPLC system was
equipped with the Shimadzu LC Solution software (Version 1.12).
Samples were chromatographed on a reversed phase C18 column
(GeminiTM 5µ, 250 x 4.6 mm).
2.3.2.2. Chromatographic conditions:
Methanol and disodium hydrogen phosphate (30 mM, adjusted to
pH 6.8 with phosphoric acid) in the ratio of 75:25 %v/v were used as
79
mobile phase. The mobile phase components were filtered before use
through a 0.45 µm membrane filter and pumped from the respective
solvent reservoirs at a flow rate of 1.0 mL/min. Eluents were monitored
using UV detection at a wavelength of 286 nm. The volume of injection
port was 20 µL.
2.3.2.3. Preparation of stock solution of famotidine:
Stock solution of famotidine was prepared by dissolving 50 mg of
famotidine with methanol in a 50 mL volumetric flask. This stock
solution was suitably diluted with mobile phase to give 100 µg/mL
(intermediate stock solution).
2.3.2.4. Preparation of stock solution of internal standard (IS):
50 mg of the ranitidine (as IS) was dissolved in triple distilled
water in a 50 mL volumetric flask and the solution was made up to
mark. This IS stock solution was diluted with mobile phase to get
10 µg/mL.
2.3.2.5. Procedure:
Plasma standard solutions (15, 30, 45, 90, 180, 270, 360, 450
and 500 ng/mL) of famotidine were prepared by taking 900 µL of drug
free human plasma in 5 mL polyprolylene tubes and 100 µL of
famotidine working standard solutions containing 150, 300, 450, 900,
1800, 2700, 3600, 4500 and 5000 ng/mL (prepared from intermediate
stock solution). 50 µL of IS (10 µg/mL) was added to above solutions
and vortex mixed for 30 seconds using a Remi cyclo mixer. 1 mL of
acetonitrile and 0.5 mL of methanol were added to the above mixtures,
80
for precipitation of plasma proteins. The samples were vortex mixed for
10 minutes and then centrifuged at 4000 rpm for 30 min using Remi
centrifuge. The clear supernatant solution was separated, filtered with
0.45 µm membrane filter and an aliquot of 20 µL was injected directly
into the HPLC loop injector. Similarly, controls of blank plasma (free
from drug) and blank plasma with IS were also processed in same
manner as described above and analyzed.
The quantification of chromatogram was performed using peak
area ratio of the drug to the IS and the average value for five such
determinations is taken. Calibration curve was constructed between the
plasma concentration of famotidine and peak area ratio.
2.3.2.6. Precision, accuracy and recovery:
The intra- and inter-day precision and accuracy of the present
HPLC method were estimated by subjecting the famotidine standard
solutions (30, 180 and 450 µg/mL) to HPLC for five different times on
five different days to HPLC. Precision was calculated by using the
percent relative standard deviation (% RSD or % C.V. = 100 s.d./M
where, M is the mean of the experimentally determined concentrations
and s.d. is the standard deviation of M). Accuracy is defined as the
percent relative error (% RE) and was calculated using the following
formula % RE = 100(E-T)/T where E is the experimentally determined
concentration and T is the theoretical concentration.
The relative analytical recovery for plasma at three different
concentrations of famotidine (30, 180, 450 ng/ml) was determined.
81
Known amounts of famotidine were added to drug free plasma and the
internal standard was then added. The relative recovery of famotidine
was calculated by comparing the peak areas for extracted famotidine
from spiked plasma and a standard solution of famotidine in methanol
containing internal standard with the same initial concentration (five
samples for each concentration level).
2.3.2.7. Results and discussion:
Optimum resolution of famotidine with no interference from other
components in plasma was achieved with the mobile phase used for the
assay. Ranitidine was used as an internal standard. The
chromatograms obtained for blank plasma and plasma spiked with IS
and different concentrations of famotidine are shown in Fig. 2.2.
Retention times of famotidine and IS were found to be 6.45 ± 0.05 and
8.35 ± 0.05 min respectively. The results of peak area ratio of the drug
to the IS are represented in Table 2.3. A representative calibration
curve of famotidine peak area ratio to the IS over the famotidine
concentration range of 0 to 500 ng/mL is shown in Fig. 2.3. The
calibration curve resulted in the linear least squares regression
equation: y = 0.007x - 0.0003, where x is the concentration of
famotidine (ng/mL) and y is the peak area ratio of famotidine to the IS.
A good linear relationship was observed as indicated by correlation
coefficient (r=0.9999) and the limit of detection was found to be
2 ng/mL. This calibration curve was used for the estimation of
famotidine in plasma samples of in vivo studies.
82
Fig. 2.2: HPLC Chromatograms of a) human blank plasma, b) plasma spiked with IS, c) famotidine at 15 ng/mL, d) 270 ng/mL and
e) 500 ng/mL
(a)
(c)
(d)
(e)
(b)
83
Table 2.3: Concentration versus peak area ratio
of famotidine in human plasma
Concentration of famotidine (ng/mL)
Peak area Peak area ratio Famotidine IS
15 3506 33065 0.11
30 6193 29614 0.21
45 9364 29838 0.31
90 19619 31308 0.63
180 42848 34190 1.25
270 56357 29461 1.91
360 81623 32979 2.47
450 96523 30790 3.13
500 113579 32354 3.51
Fig. 2.3: Calibration curve for the estimation of famotidine in human plasma samples
y = 0.007x - 0.0003r = 0.9999
0
0.5
1
1.5
2
2.5
3
3.5
4
0 200 400
Peak area ratio
Plasma concentrations of famotidine (ng/mL)
84
The results of precision and accuracy are represented in
Table 2.4. High precision and accuracy of the present precipitation
method was confirmed with low percent C.V. values (<5%) and low
% RE values (within ±2) respectively in intra- and inter-day estimation
of famotidine. The percentage recovery values represented in Table 2.5
revealed that this procedure is suitable for the precipitation of plasma
proteins. The results of the study indicated that the method was
sensitive, precise and accurate. Hence this method is used for the
estimation of famotidine in human plasma samples during the in vivo
studies.
Table 2.4: Precision and accuracy of the HPLC method used
for the estimation of famotidine in human plasma samples
Concentration of famotidine
(ng/mL)
Intra-day Inter-day
Mean (%, n=5)
% C.V.
% RE Mean
(%, n=5)
% C.V.
% RE
30 100.7 2.19 1.2 100.3 3.12 1.15
180 101.3 0.95 0.4 101.5 1.59 0.54
450 100.1 2.35 0.9 99.7 3.14 -0.15
Table 2.5: Relative recovery of famotidine from plasma
Famotidine spiked
concentration
(ng/mL)
Famotidine
concentration found
(ng/mL, Mean, n=5)
% recovery
(Mean ± s.d.)
30 30.63 102.1 ± 0.98
180 182.16 101.2 ± 1.52
450 449.51 99.89 ± 3.31
2.4. Studies on interference of famotidine with the excipients used
in the present investigation:
85
In the present investigation, PEO and glyceryl behenate are used
as rate controlling polymer and wax material respectively along with
other excipients (like sodium bicarbonate, Aerosil, magnesium stearate
and lactose) for the development of gastric floating matrix tablets
(GFMT) of famotidine. The excipients used could cause interference in
the estimation of famotidine by UV spectrophotometric method. Hence,
a study was made to check for the interference of the proposed
excipients of the formulations with famotidine.
Accurately weighed amounts of drug and excipients (in 1:1 w/w
ratio) separately were mixed thoroughly in a mortar using pestle. From
each mixture, an accurately weighed powder equivalent to 50 mg of
famotidine was transferred into 50 mL volumetric flask. The drug was
extracted with 40 mL of 0.1N HCl with vigorous shaking on mechanical
shaker for 1 hr and filtered into a 50 mL volumetric flask using
0.45 µm Millipore nylon filter disc. The filtrate was made up to the
mark with 0.1N HCl. Then the solution was suitably diluted with
0.1N HCl and assayed for famotidine by the UV spectrophotometric
method described in Sec. 2.3.1.
2.4.1. Results and discussion:
The results of famotidine estimated in interference study are
shown in the Table 2.6. The results indicated that none of the
materials interfered with famotidine estimation in UV spectroscopic
method. Thus the method was found to be suitable in the present
investigation for the estimation of drug in the in vitro samples.
86
Table 2.6: Percent of drug estimated in interference study
Excipient famotidine estimated (%, mean±s.d., n=3)
PEO WSR 303 100.13 ± 1.02
PEO WSR N-12K 99.29 ± 0.92
Glyceryl behenate 99.93 ± 0.38
Sodium bicarbonate 99.75 ± 1.20
Aerosil 99.84 ± 0.84
Magnesium stearate 99.81 ± 1.02
Lactose 99.89 ± 1.28
2.5. Calculation of initial dose and maintenance dose for the
design of gastric floating drug delivery systems of famotidine for 12 hours:
There are no sustained release formulations for famotidine in the
market, hence the total dose (DT) consisting of initial (DI) and
maintenance doses (DM) for formulating the famotidine sustained
release was calculated as per Robinson and Eriksen equation with a
zero order release principle56. In this profile the rate of delivery is
independent of the amount of drug remaining in the dosage form and
constant over time as shown by the Eq. 2.1.
Drug availability rate k0 = Rate in = Rate out Eq. 2.1
Where, k0 is the zero order rate constant for drug release (amount
per time).
DI is required to give initial rapid release of drug so as to attain
the minimum therapeutic level immediately after dosing.
Eq. 2.2 ( )
=
F
VCD dose Initial
davgss
I
87
Where, Cssavg is the average steady state plasma level, Vd is the volume
of distribution and F is the fraction of dose absorbed.
k0 = DIKel Eq. 2.3
Where, Kel is overall first order drug elimination rate constant (per
hour). Hence k0 should be equal to the elimination rate constant so as
to maintain the steady state condition.
In general the total dose required (DT) is the sum of the
maintenance dose (DM) and the initial dose (DI).
DT = DI + DM Eq. 2.4
In practice, DM (mg) is released over a period of time and is equal
to the product of H (the number of hours for which sustained action is
desired after initial dose) and the zero order rate constant, k0 (mg/hr).
Therefore the Eq. 2.4 can be expressed as
DT = DI + k0H Eq. 2.5
Ideally the maintenance dose (DM) is released after DI has
produced a minimum therapeutic blood level of the drug. However due
to the limits of formulations, drug release even starts from DM also from
the beginning i.e. at t=0, thus increasing the initial drug level in the
blood. Hence it is necessary to reduce the initial dose of the drug to
account for the excess release for drug from DM by using a correction
factor, k0tp. This correction factor is the amount of drug provided by DM
during the period from t=0 to the time of the peak drug level, tp. The
corrected initial dose (DI*) becomes DI-(k0tp). Then the total dose is
DT = DI* + k0H = (DI - k0tp) + k0H Eq. 2.6
88
2.5.1. Pharmacokinetic parameters of famotidine:
Elimination half life (t1/2) of famotidine is 3 hrs (average of 2.5 to
3.5 hrs), the time to reach peak plasma (tp) is 2 hrs and Vd = 91 L and
F = 0.49,11. From the literature of the PEPCID (innovator product of
famotidine in USA) label and pharmacological review information4,6, it
was found that the plasma levels after multiple doses are similar to
those after single doses indicating the Cmax is similar to Cssavg, therefore
Cmax of 0.07 mg/L was taken as Cssavg.
2.5.2. Calculation of DI and DM:
The initial dose (DI), corrected initial dose (DI*), maintenance dose
(DM) and total dose (DT) were calculated according to calculations
described above.
2.5.2.1. Calculation of elimination rate constant:
Elimination rate constant (Kel) = 0.693/t1/2
= 0.693/3 = 0.231 hr-1
2.5.2.2. Calculation of initial dose:
= (0.07 X 91)/0.4
= 15.93 mg
2.5.2.3. Calculation of desired input rate (k0):
Desired input rate from maintenance dose (k0) = DIKel
( )
=
F
VCD dose Initial
davgss
I
89
= 15.93 X 0.231 = 3.68 mg/hr
2.5.2.4. Calculation of maintenance dose:
Maintenance dose (DM) = k0H (Since, H = the number of hours for
which sustained action is desired after initial dose = (12-1) = 11 hrs)
= 3.68 X 11 = 40.48 mg
2.5.2.5. Calculation of corrected initial dose DI*:
DI* = DI – (k0tp) = 15.93 – (3.68 X 2) = 8.57 mg
2.5.2.6. Calculation of total dose:
Total dose (DT) = DI* + DM
= 8.57 + 40.48 = 49.05 mg
From the above calculations the total dose obtained for sustained
release of famotidine for 12 hrs is 49.05 mg. The total dose was
rounded off to 50 mg for the convenience. Initially the dosage form
should release the total initial dose (i.e. 8.57 mg ~ 9.0 of drug, means
18% of total 50 mg dose) in the first 1 hr followed by maintenance dose
(i.e. 50-9=41 mg of drug) for up to 12 hrs thereafter at a release rate of
3.68 mg/hr (i.e. 7.36% of total 50 mg dose). Based on these
assumptions the theoretical release profile was predicted and shown in
Table 2.7 and Fig. 2.4
90
Table 2.7: Predicted theoretical release profile
Time (hrs) % drug release
1 18 2 25 3 33 4 40 5 47 6 55 8 70 10 84 12 99
Time (hrs)
% drug release
0 3 6 9 120
20
40
60
80
100
Fig. 2.4: Predicted theoretical release profile
91
REFERENCES
1. Moffat AC, Osselton MD and Widdop B: Clarks Analysis of Drugs and Poisons, Pharmaceutical Press, London, 3rd Edn., 2004, pp 1015-1016.
2. Campoli-Richards DM and Clissold SP: Famotidine: Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. 32: 197-221, 1986.
3. Ryan JR, Vargas R, McMahon FG and Chremos AN: Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion. Am J Med. 81: 60-4, 1986.
4. Pepcid AC review, www.accessdata.fda.gov/drugsatfda_docs/ nda/2007/020801Orig1s012.pdf. accessed on 30th Dec 2007.
5. Chremos AN: Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol. 9: 7-12, 1987.
6. Pepcid Label information, www.accessdata.fda.gov/drugsatfda_ docs/label/2007/019462s034,019510s031,020249s013lbl.pdf. accessed on 24-06-2007.
7. Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD and Jensen RT: Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterol. 88: 1026-1033, 1985.
8. TIAFT reference blood level list of therapeutic and toxic substances, www.gtfch.org/cms/images/stories/Updated_TIAFT_list_202005. pdf, September 2004. accessed on 3rd Oct 2007.
9. Echizen H and Ishizaki T: Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 21: 178-94, 1991.
10. Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, Nakamura S, Ushiogi Y, Kawabata M, Hashimoto N et al.: Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. Eur J Clin Pharmacol. 28: 327-31, 1985.
11. Harman JG and Limbird LE: Histamins bradykinin and their antagonists: Goodman and Gilman's The Pharmacological basis of Therapeutics, McGraw Hill Publications, New York, USA, 2001, pp 645-667.
12. Rang HP, Dale MM, Ritter JM, Flower RJ and Henderson G: Rang and Dale's Pharmacology: The gastrointestinal tract, Elsevier Churchill Livingstone, New Yark, USA, 2012, pp 360-371.
13. Dicenta C, Pierzchala PA, Rhymer AR and Jaffe ME: Outline of clinical studies with a new H2-antagonist: famotidine. Ital J Gastroenterol. 16: 181-182, 1984.
92
14. Kibbe AH: Hand book of Pharmaceutical excipients. American Pharmaceutical Association, Washington DC, USA, 2000.
15. Witt C, Mader K and Kissel T: The degradation, swelling and erosion properties of biodegradable implants prepared by extrusion or compression moulding of poly(lactide-co-glycolide) and ABA triblock copolymers. Biomater. 21: 931-938, 2000.
16. Washburn NR, Simon CG, Jr., Tona A, Elgendy HM, Karim A and Amis EJ: Co-extrusion of biocompatible polymers for scaffolds with co-continuous morphology. J Biomed Mater Res. 60: 20-9, 2002.
17. Rades T and Mueller-Goymann CC: Interactions between fenoprofen sodium and poly (ethylene oxide). Eur J Pharm Biopharm. 46: 51-59, 1998.
18. Efentakis M, Koutlis A and Vlachou M: Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems. AAPS Pharm Sci Tech. 1: 62-70, 2000.
19. Liu L, Khang G, Rhee JM and Lee HB: Monolithic osmotic tablet system for nifedipine delivery. J Control Rel. 67: 309-322, 2000.
20. Repka MA and McGinity JW: Influence of vitamin E TPGS on the properties of hydrophilic films produced by hot-melt extrusion. Int J Pharm. 202: 63-70, 2000.
21. Repka MA, Prodduturi S and Stodghill SP: Production and Characterization of Hot-Melt Extruded Films Containing Clotrimazole. Drug Dev Ind Pharm. 29: 757-765, 2003.
22. Crowley MM, Zhang F, Koleng JJ and McGinity JW: Stability of polyethylene oxide in matrix tablets prepared by hot-melt extrusion. Biomaterials. 23: 4241-8, 2002.
23. USP29/NF24: Polyethylene oxide, United States Pharmacopeial Convention, Rock-Ville, Maryland, USA. 3398-3399, 2006.
24. POLYOX Water-Soluble Resins, http://www.dow.com/ inspecpolymers/prod/polyox.htm. accesssed on 24-05-2008.
25. Compritol® 888 ATO, http://www.gattefosse.com/node.php? articleid=172. accessed on 24-06-2009.
26. Barthelemy P, Laforêt JP, Farah N and Joachim J: Compritol® 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm. 47: 87-90, 1999.
27. Faham A, Prinderre P, Farah N, Eichler KD, Kalantzis G and Joachim J: Hot-melt coating technology. I. Influence of Compritol 888 ATO and granule size on theophylline release. Drug Dev Ind Pharm. 26: 167-76, 2000.
28. Faham A, Prinderre P, Piccerelle P, Farah N and Joachim J: Hot melt coating technology: influence of Compritol 888 ATO and granule size on chloroquine release. Pharmazie. 55: 444-8, 2000.
93
29. Hamdani J, Moës AJ and Amighi K: Development and in vitro evaluation of a novel floating multiple unit dosage form obtained by melt pelletization. Int J Pharm. 322: 96-103, 2006.
30. Zhang YE and Schwartz JB: Melt granulation and heat treatment for wax matrix-controlled drug release. Drug Dev Ind Pharm. 29: 131-8, 2003.
31. Freitas C and Muller RH: Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 47: 125-32, 1999.
32. USP29/NF24: Glyceryl behenate, United States Pharmacopeial Convention, Rock-Ville, Maryland, USA. 3340-3341, 2006.
33. Brossard C, Ratsimbazafy V and des Ylouses DL: Modelling of Theophylline Compound Release from Hard Gelatin Capsules Containing Gelucire Matrix Granules. Drug Dev Ind Pharm. 17: 1267-1277, 1991.
34. Volkhard Jenning SHG: Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul. 18: 149-158, 2001.
35. Achanta AS, Adusumilli PS, James KW and Rhodes CT: Hot-Melt Coating: Water Sorption Behavior of Excipient Films. Drug Dev Ind Pharm. 27: 241-250, 2001.
36. Achanta AS, Adusumilli PS, James KW and Rhodes CT: Thermodynamic Analysis of Water Interaction with Excipient Films. Drug Dev Ind Pharm. 27: 227-240, 2001.
37. Hariharan M, Wowchuk C, Nkansah P and Gupta VK: Effect of Formulation Composition on the Properties of Controlled Release Tablets Prepared by Roller Compaction. Drug Dev Ind Pharm. 30: 565-572, 2004.
38. Obaidat AA and Obaidat RM: Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate. Eur J Pharm Biopharm. 52: 231-5, 2001.
39. Jannin V, Bérard V, N'Diaye A, Andrès C and Pourcelot Y: Comparative study of the lubricant performance of Compritol® 888 ATO either used by blending or by hot melt coating. Int J Pharm. 262: 39-45, 2003.
40. Ashiru DAI, Patel R and Basit AW: Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: Application to the analysis of ranitidine and its metabolites in human volunteers. Journal of Chromatography B. 860: 235-240, 2007.
41. Helali N, Darghouth F and Monser L: RP-HPLC Determination of Famotidine and its Potential Impurities in Pharmaceuticals. Chromatographia. 60: 455-460, 2004.
42. Tzanavaras PD, Verdoukas A and Balloma T: Optimization and validation of a dissolution test for famotidine tablets using flow injection analysis. J Pharm Biomed Anal. 41: 437-441, 2006.
94
43. Zarghi A, Shafaati A, Foroutan SM and Khoddam A: Development of a rapid HPLC method for determination of famotidine in human plasma using a monolithic column. J Pharm Biomed Anal. 39: 677-680, 2005.
44. Wanwimolruk S, Zoest AR, Wanwimolruk SZ and Hung CT: Sensitive high-performance liquid chromatographic determination of famotidine in plasma: Application to pharmacokinetic study. J Chromato B: Biomed Sci Applicat. 572: 227-238, 1991.
45. Bologna M, Napolitano T, Biordi L and Carlucci G: HPLC reveals famotidine in the urine up to five days after a single 20 mg oral dose. Drugs Exp Clin Res. 14: 419-21, 1988.
46. Dragicazendelovska and Traje S: High-performance liquid chromatographic determination of famotidine in human plasma using solid-phase column extraction. J Serb Chem Soc. 68: 883-892, 2003.
47. Pawar SM, Patil BS and Dave RY: Validated HPTLC method for simultaneous quantitation of famotidine and domperidone in bulk drug and formulation. Int J Adv in Pharm Sci. 1: 54-59, 2010.
48. Kelani KM, Aziz AM, Hegazy MA and Farrah LA: Determination of cimetidine, famotidine, and ranitidine hydrochloride in the presence of their sulfoxide derivatives in pure and dosage forms by high-performance thin-layer chromatography and scanning densitometry. J AOAC Int. 85: 1015-20, 2002.
49. Novakovic J: High-performance thin-layer chromatography for the determination of ranitidine hydrochloride and famotidine in pharmaceuticals. J Chromat A. 846: 193-198, 1999.
50. Qin XZ, Ip DP, Chang KH, Dradransky PM, Brooks MA and Sakuma T: Pharmaceutical application of LC-MS. 1-Characterization of a famotidine degradate in a package screening study by LC-APCI MS. J Pharm Biomed Anal. 12: 221-33, 1994.
51. Zhong L, Eisenhandler R and Yeh KC: Determination of famotidine in low-volume human plasma by normal-phase liquid chromatography/tandem mass spectrometry. J Mass Spectrom. 36: 736-41, 2001.
52. Sun X, Tian Y, Zhang Z and Chen Y: A single LC-tandem mass spectrometry method for the simultaneous determination of four H2 antagonists in human plasma. J Chromato B. 877: 3953-3959, 2009.
53. Furtado S, Deveswaran R, Bharath S, Basavaraj BV, Abraham S and Madhavan V: Development and characterization of orodispersible tablets of famotidine containing a subliming agent. Trop J Pharm Res. 7: 1185-1189, 2008.
95
54. Deveswaran R, Furtado S, Bharath S, Abraham S, Basavaraj BV and Madhavan V: Evaluation of Disintegrant Properties of Plantago Ovata Mucilage in Comparison with other Superdisintegrants. Arch Pharm Sci Res. 2: 230 - 235, 2010.
55. USP29/NF24: Famotidine, United States Pharmacopeial Convention, Rock-Ville, Maryland, USA. 881-882, 2006.
56. Robinson JR and Eriksen SP: Theoretical formulation of sustained-release dosage forms. J Pharm Sci. 55: 1254-1263, 1966.